
A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study



A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Background


- Background: Randomized, double-blind, phase 3, placebo-controlled trial of a dapivirine-containing vaginal ring changed every 4 weeks as compared to a placebo ring for HIV-1 prevention for women at multiple sites in 7 communities in South Africa and Uganda
- Inclusion Criteria (n = 1,959 enrolled)
 - 18-45 years of age
 - HIV seronegative
 - Sexually active
 - Nonpregnant and on stable contraceptive
- Treatment Arms
 - Dapivirine 25 mg vaginal ring, changed monthly
 - Placebo vaginal ring, changed monthly





A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Results


Incidence Rate for New HIV Infections





A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Results


Incidence Rate: Risk Reduction Compared with Placebo





A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Results

Relative Risk Reduction, by Age





A Vaginal Ring Containing Dapivirine for HIV-1 PrEP Ring Study: Conclusions

Conclusions: "Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo."



Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.





